التفاصيل البيبلوغرافية
| العنوان: |
Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group. |
| المؤلفون: |
Haneveld, Mirthe J. Klein, van Treijen, Mark J. C., Pieterman, Carolina R. C., Dekkers, Olaf M., van de Ven, Annenienke, de Herder, Wouter W., Zandee, Wouter T., Drent, Madeleine L., Bisschop, Peter H., Havekes, Bas, Vriens, Menno R., Stuart, Annemarie A. Verrijn, Valk, Gerlof D., van Leeuwaarde, Rachel S., Klein Haneveld, Mirthe J, Verrijn Stuart, Annemarie A |
| المصدر: |
Journal of Clinical Endocrinology & Metabolism; Dec2021, Vol. 106 Issue 12, p3515-3525, 11p |
| مصطلحات موضوعية: |
NEUROENDOCRINE tumors, MORTALITY, AGE groups, PANCREATIC tumors, DATABASES, ANTHROPOMETRY, EARLY detection of cancer, RETROSPECTIVE studies, PROGNOSIS, DIAGNOSTIC imaging, WERMER syndrome, AGE factors in disease, LONGITUDINAL method |
| مصطلحات جغرافية: |
NETHERLANDS |
| مستخلص: |
Context: Nonfunctioning pancreatic neuroendocrine tumors (NF-pNETs) are highly prevalent and constitute an important cause of mortality in patients with multiple endocrine neoplasia type 1 (MEN1). Still, the optimal age to initiate screening for pNETs is under debate.Objective: The aim of this work is to assess the age of occurrence of clinically relevant NF-pNETs in young MEN1 patients.Methods: Pancreatic imaging data of MEN1 patients were retrieved from the DutchMEN Study Group database. Interval-censored survival methods were used to describe age-related penetrance, compare survival curves, and develop a parametric model for estimating the risk of having clinically relevant NF-pNET at various ages. The primary objective was to assess age at occurrence of clinically relevant NF-pNET (size ≥ 20 mm or rapid growth); secondary objectives were the age at occurrence of NF-pNET of any size and pNET-associated metastasized disease.Results: Five of 350 patients developed clinically relevant NF-pNETs before age 18 years, 2 of whom subsequently developed lymph node metastases. No differences in clinically relevant NF-pNET-free survival were found for sex, time frame, and type of MEN1 diagnosis or genotype. The estimated ages (median, 95% CI) at a 1%, 2.5%, and 5% risk of having developed a clinically relevant tumor are 9.5 (6.5-12.7), 13.5 (10.2-16.9), and 17.8 years (14.3-21.4), respectively.Conclusion: Analyses from this population-based cohort indicate that start of surveillance for NF-pNETs with pancreatic imaging at age 13 to 14 years is justified. The psychological and medical burden of screening at a young age should be considered. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Endocrinology & Metabolism is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder